Statins May Help Block Transmission of Lyme Disease
By LabMedica International staff writers Posted on 27 May 2016 |

Image: A dark field photomicrograph showing the spirochete bacterium Borrelia burgdorferi, the pathogen responsible for causing Lyme disease (Photo courtesy of the CDC).
A recent study found that treatment with cholesterol-lowering statins reduced the number of Borrelia burgdorferi bacteria in rodents, which helped to block transmission of Lyme disease.
Lyme disease is a systemic disorder caused by the spirochete bacterium Borrelia burgdorferi. This bacterium is transmitted to mammalian hosts from arthropod vectors, specifically Ixodes spp. ticks. Lyme disease is the most prevalent arthropod borne disease in the USA with over 25,000 cases confirmed by the Centers for Disease Control and Prevention in 2014.
Investigators at the University of Texas at San Antonio (USA) decided to attack B. burgdorferi through its 3-hydroxy-3-methyl-glutaryl-coenzyme A reductase, which serves as a rate limiting enzyme of the mevalonate pathway that contributes to the synthesis of components critical for building the bacterium's cell wall.
In this study C3H/HeN mice, with or without statin treatment, were infected with 1000 spirochetes per mouse. The spirochetes were found to spread to all tissues with a few exceptions. Though there was no significant difference in bacterial dissemination to distal tissues between statin-treated and untreated mice, the investigators wanted to determine whether there were differences in the numbers of bacteria migrating to specific tissues. To that end, total genomic DNA was extracted from a portion of skin, spleen, right inguinal lymph node, and right tibiotarsal joint and subjected to quantitative real-time PCR analysis using primers specific for B. burgdorferi genes.
Results published in the March 16, 2016, online edition of the journal Microbes and Infection revealed that there was a significant decrease in the numbers of bacteria in each of the tissues tested with the exception of the joints. There were higher levels of reduction seen in the lymph nodes and spleens of mice treated with simvastatin when compared to the same tissues from mice treated with lovastatin, while there was a higher level of reduction in the skin of lovastatin-treated mice.
"We have figured out that there is one enzyme in the Lyme disease bacteria that is essential for creating its cell wall, which would allow the Lyme disease bacteria to live and cause infection," said senior author Dr. Janakiram Seshu, associate professor of biology at the University of Texas at San Antonio. "We discovered that this enzyme can be inhibited by statins, which means that one class of drugs could reduce the number of infectious bacteria in the reservoir hosts. First we want to determine how statins can be used to stop the growth of the pathogen and how we can exploit these findings to our benefit. Our hope is that if we reduce the number of viable organisms in infected reservoir hosts then we can block the transmission to a point that the disease does not affect humans significantly in many areas of the USA."
Related Links:
University of Texas at San Antonio
Lyme disease is a systemic disorder caused by the spirochete bacterium Borrelia burgdorferi. This bacterium is transmitted to mammalian hosts from arthropod vectors, specifically Ixodes spp. ticks. Lyme disease is the most prevalent arthropod borne disease in the USA with over 25,000 cases confirmed by the Centers for Disease Control and Prevention in 2014.
Investigators at the University of Texas at San Antonio (USA) decided to attack B. burgdorferi through its 3-hydroxy-3-methyl-glutaryl-coenzyme A reductase, which serves as a rate limiting enzyme of the mevalonate pathway that contributes to the synthesis of components critical for building the bacterium's cell wall.
In this study C3H/HeN mice, with or without statin treatment, were infected with 1000 spirochetes per mouse. The spirochetes were found to spread to all tissues with a few exceptions. Though there was no significant difference in bacterial dissemination to distal tissues between statin-treated and untreated mice, the investigators wanted to determine whether there were differences in the numbers of bacteria migrating to specific tissues. To that end, total genomic DNA was extracted from a portion of skin, spleen, right inguinal lymph node, and right tibiotarsal joint and subjected to quantitative real-time PCR analysis using primers specific for B. burgdorferi genes.
Results published in the March 16, 2016, online edition of the journal Microbes and Infection revealed that there was a significant decrease in the numbers of bacteria in each of the tissues tested with the exception of the joints. There were higher levels of reduction seen in the lymph nodes and spleens of mice treated with simvastatin when compared to the same tissues from mice treated with lovastatin, while there was a higher level of reduction in the skin of lovastatin-treated mice.
"We have figured out that there is one enzyme in the Lyme disease bacteria that is essential for creating its cell wall, which would allow the Lyme disease bacteria to live and cause infection," said senior author Dr. Janakiram Seshu, associate professor of biology at the University of Texas at San Antonio. "We discovered that this enzyme can be inhibited by statins, which means that one class of drugs could reduce the number of infectious bacteria in the reservoir hosts. First we want to determine how statins can be used to stop the growth of the pathogen and how we can exploit these findings to our benefit. Our hope is that if we reduce the number of viable organisms in infected reservoir hosts then we can block the transmission to a point that the disease does not affect humans significantly in many areas of the USA."
Related Links:
University of Texas at San Antonio
Latest BioResearch News
- Genome Analysis Predicts Likelihood of Neurodisability in Oxygen-Deprived Newborns
- Gene Panel Predicts Disease Progession for Patients with B-cell Lymphoma
- New Method Simplifies Preparation of Tumor Genomic DNA Libraries
- New Tool Developed for Diagnosis of Chronic HBV Infection
- Panel of Genetic Loci Accurately Predicts Risk of Developing Gout
- Disrupted TGFB Signaling Linked to Increased Cancer-Related Bacteria
- Gene Fusion Protein Proposed as Prostate Cancer Biomarker
- NIV Test to Diagnose and Monitor Vascular Complications in Diabetes
- Semen Exosome MicroRNA Proves Biomarker for Prostate Cancer
- Genetic Loci Link Plasma Lipid Levels to CVD Risk
- Newly Identified Gene Network Aids in Early Diagnosis of Autism Spectrum Disorder
- Link Confirmed between Living in Poverty and Developing Diseases
- Genomic Study Identifies Kidney Disease Loci in Type I Diabetes Patients
- Liquid Biopsy More Effective for Analyzing Tumor Drug Resistance Mutations
- New Liquid Biopsy Assay Reveals Host-Pathogen Interactions
- Method Developed for Enriching Trophoblast Population in Samples
Channels
Clinical Chemistry
view channel
New Reference Measurement Procedure Standardizes Nucleic Acid Amplification Test Results
Nucleic acid amplification tests (NAATs) play a key role in diagnosing a wide range of infectious diseases. These tests are generally known for their high sensitivity and specificity, and they can be developed... Read more
Pen-Like Tool Quickly and Non-Invasively Detects Opioids from Skin
Opioid drugs such as fentanyl, morphine, and oxycodone are the primary substances associated with overdose cases in the United States. Standard drug screening procedures typically involve collecting blood,... Read moreMolecular Diagnostics
view channel
New Blood Test for Leukemia Risk Detection Could Replace Bone Marrow Sampling
Myelodysplastic syndrome (MDS) is a condition typically associated with aging, where blood stem cells fail to develop into fully functional blood cells. Early and accurate diagnosis is vital, as MDS can... Read more
Blood Test Detects Preeclampsia Risk Months Before Symptoms Appear
Preeclampsia, a pregnancy-related complication characterized by elevated blood pressure and organ dysfunction, remains a major contributor to maternal and infant health issues globally. Existing screening... Read moreHematology
view channel
Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results
Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more
First Point-of-Care Heparin Monitoring Test Provides Results in Under 15 Minutes
Heparin dosing requires careful management to avoid both bleeding and clotting complications. In high-risk situations like extracorporeal membrane oxygenation (ECMO), mortality rates can reach about 50%,... Read moreImmunology
view channel
Blood Test Detects Organ Rejection in Heart Transplant Patients
Following a heart transplant, patients are required to undergo surgical biopsies so that physicians can assess the possibility of organ rejection. Rejection happens when the recipient’s immune system identifies... Read more
Liquid Biopsy Approach to Transform Diagnosis, Monitoring and Treatment of Lung Cancer
Lung cancer continues to be a major contributor to cancer-related deaths globally, with its biological complexity and diverse regulatory processes making diagnosis and treatment particularly difficult.... Read more
Computational Tool Exposes Hidden Cancer DNA Changes Influencing Treatment Resistance
Structural changes in tumor DNA are among the most damaging genetic alterations in cancer, yet they often go undetected, particularly when tissue samples are degraded or of low quality. These hidden genomic... Read moreMicrobiology
view channel
Credit Card-Sized Test Boosts TB Detection in HIV Hotspots
Current tuberculosis (TB) tests face major limitations when it comes to accurately diagnosing the infection in individuals living with HIV. HIV, a frequent co-infection with TB, complicates detection by... Read more
Fecal Metabolite Profiling Predicts Mortality in Critically Ill Patients
Critically ill patients in medical intensive care units (MICUs) often suffer from conditions such as acute respiratory distress syndrome (ARDS) or sepsis, which are linked to reduced diversity of gut microbiota... Read more
Portable Molecular POC System Rules Out UTIs in Just 35 Minutes
Urinary tract infections (UTIs) represent a massive burden on patients and healthcare systems. There are over 400 million UTI cases globally each year, of which around 90% are in women. Fast and accurate... Read more
POC Lateral Flow Test Detects Deadly Fungal Infection Faster Than Existing Techniques
Diagnosing mucormycosis—an aggressive and often deadly fungal infection—remains a major challenge due to the disease’s rapid progression and the lack of fast, accurate diagnostic tools. The problem became... Read morePathology
view channel
Cancer Chip Accurately Predicts Patient-Specific Chemotherapy Response
Esophageal adenocarcinoma (EAC), one of the two primary types of esophageal cancer, ranks as the sixth leading cause of cancer-related deaths worldwide and currently lacks effective targeted therapies.... Read more
Clinical AI Solution for Automatic Breast Cancer Grading Improves Diagnostic Accuracy
Labs that use traditional image analysis methods often suffer from bottlenecks and delays. By digitizing their pathology practices, labs can streamline their work, allowing them to take on larger caseloads... Read more
Saliva-Based Testing to Enable Early Detection of Cancer, Heart Disease or Parkinson’s
Saliva is one of the most accessible biological fluids, yet it remains underutilized in clinical practice. While saliva samples are used to perform genetic tests to determine, for example, paternity, the... Read moreTechnology
view channel
New POC Biosensing Technology Improves Detection of Molecular Biomarkers
Traditional diagnostic procedures in medicine typically involve sending a patient’s blood or tissue samples to clinical laboratories, where trained scientists perform testing and data interpretation.... Read more
Enhanced Lab Data Management and AI Critical to Labs of the Future, Finds Survey
Data plays a key role in the transformation of today’s digital laboratories, acting both as a key challenge and a catalyst for innovation, as revealed by a survey of over 150 scientists.... Read moreIndustry
view channel
AMP Releases Best Practice Recommendations to Guide Clinical Laboratories Offering HRD Testing
Homologous recombination deficiency (HRD) testing identifies tumors that are unable to effectively repair DNA damage through the homologous recombination repair pathway. This deficiency is often linked... Read more